Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01878461 · ClinicalTrials.gov registry record · Phase 3
Evaluate the Efficacy and Safety of M518101 in Subjects With Plaque Psoriasis
A Phase 3 study of Psoriasis, sponsored by Maruho North America.
- Completed
- Registry status
- Phase 3
- Development phase
- 542
- Enrollment target
- 20
- Study locations
NCT01878461: Completed Phase 3 study of Psoriasis, sponsored by Maruho North America.
NCT01878461 is a Phase 3 study of Psoriasis that has completed, run by Maruho North America. The registered enrollment target is 542 participants, above the 484-participant average among 125 other Psoriasis trials with a reported enrollment target (12% higher). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01878461, a Phase 3 study of Psoriasis, has completed, sponsored by Maruho North America.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 542 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is to evaluate the efficacy and safety of M518101 in subjects with plaque psoriasis
Conditions Studied
Interventions
- DRUG Vehicle
- DRUG M518101
Study Locations (20)
California
- T Joseph Raoof - Encino
- Medical Center for Clinical Research - San Diego
- Therapeutics Clinical Research - San Diego
- Clinical Science Institute - Santa Monica
Florida
- The Center for Clinical and Cosmetic Research - Aventura
- Jacksonville Center for Clinical Research - Jacksonville
Kentucky
- Derm Research - Louiville
- Dermatology Specialists Research - Lousville
Nevada
- Karl G Heine Dermatology - Henderson
- Las Vegas Skin and Cancer Center - Las Vegas
Arizona
- Agave Clinical Research - Mesa
Colorado
- Horizons Clinical Research Center - Denver
Illinois
- Northshore University Health System - Skokie
Indiana
- South Bend Clinic - South Bend
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 542 participants |
| Start Date | 2013-06 |
| Est. Completion | 2015-05 |
| Phase | Phase 3 |
What the finished NCT01878461 record still lists
NCT01878461 is an interventional study that assigns participants to a tested intervention. The registered 542 participants enrollment target is mid-sized for trials with a published cap, above the 484-participant average among 125 other Psoriasis trials with a reported enrollment target (12% higher).
The record links to 1 condition, with Psoriasis appearing as the primary indexed condition, and to 2 interventions - of which Vehicle is the first listed.
NCT01878461 names 20 study sites across 14 states, led by California, Florida, Kentucky.
Frequently Asked Questions
What is clinical trial NCT01878461 about?
NCT01878461 is a clinical study titled "Evaluate the Efficacy and Safety of M518101 in Subjects With Plaque Psoriasis". This study is to evaluate the efficacy and safety of M518101 in subjects with plaque psoriasis
What is the current status of trial NCT01878461?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 542 participants. The study started on 2013-06. Estimated completion is 2015-05.
What conditions does trial NCT01878461 study?
This clinical trial studies the following conditions: Psoriasis.
What interventions are being tested in trial NCT01878461?
The interventions under investigation include: Vehicle (DRUG), M518101 (DRUG).
Who is sponsoring clinical trial NCT01878461?
This trial is sponsored by Maruho North America, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01878461 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01878461's enrollment target sits among peer trials
542 17th of 125 higher than 109 of 125 other Psoriasis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Psoriasis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977
ACTIVE NOT RECRUITING · Phase 3
-
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
ACTIVE NOT RECRUITING · Phase 3
-
Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis
ACTIVE NOT RECRUITING · Phase 3
-
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04929223 · 542 participants · Phase 1
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
- NCT05584670 · 542 participants · Phase 1
A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors
- NCT07294053 · 543 participants · NA
Sugary Drink Labeling Study
- NCT03127761 · 544 participants
Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries With Multiple Myeloma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia